Rationale of Cytoreductive Surgery and HIPEC for Management Ovarian Cancer

Abstract

    Ovarian cancer is the second most common genital malignancy in women and it is the most lethal gynecological malignancy. The most common cause of primary ovarian malignancy is epithelial carcinoma; however its exact cause has not yet been identified. Determining the optimal management of patients with advanced ovarian cancer is a significant challenge. The standard of care for ovarian cancer has been surgery followed by systemic chemotherapy. However, treatment with cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC) is another approach, showing promising results. CRS and HIPEC have become widely accepted as an effective method of treating peritoneal metastases (PM) from various cancers. Therefore,  this study  aimed to review the surgical management using cytoreductive surgery and HIPEC for  treatment of advanced ovarian cancer.